Skip to main content
The Motley Fool
Helping the world invest better since 1993.
Hi, Fool! Premium Advice
Help
Login
The Motley Fool
Latest Stock Picks
Stocks
How to Invest
Retirement
Personal Finance
Community
Search
Ticker or Keyword
Go
The 4 Largest Pure-Play Marijuana Stocks
There are now four pot stocks with a market cap in excess of $1 billion.
Sean Williams (TMFUltraLong) Nov 17, 2017 at 8:21AM
Marijuana hasn't come by the nickname "the green rush" by accident. If we take a closer look at the performance of marijuana stocks, most have had investors seeing a lot of green over the trailing year. In many instances, pot stocks have rallied by 100% or more as sales growth for legal weed soars and expansion opportunities into new U.S. states and foreign countries appears promising.
At the heart of this surge can be found a major shift in the way consumers view cannabis. Gallup, which has taken national surveys on pot for 48 years, found that 64% of respondents support the idea of legalizing the drug nationally as of Oct. 2017. Comparatively, just 25% supported the same idea in 1995, the year before California became the first state to legalize medical cannabis for compassionate use. The industry has come a long way in a relatively short period of time, and it's translated into big wins for most marijuana stock investors.
A cannabis leaf covering Ben Franklin's face on a hundred dollar bill, with only his eyes exposed.
IMAGE SOURCE: GETTY IMAGES.
The largest pure-play marijuana stocks
In fact, some pot stocks are now sporting market caps large enough -- in excess of $1 billion -- that they could garner the attention of Wall Street and longer-term investors. Here's a brief look at the four largest pure-play marijuana stocks by market cap, through Nov. 10, 2017. You'll note the use of the term "pure-play," which excludes companies like Scotts Miracle-Gro and Arena Pharmaceuticals, which have respective market caps of $5.76 billion and $1.05 billion, but only have a small portion of their business devoted to cannabis.
Canopy Growth Corp: $3.02 billion
Don't let your eyes deceive you -- there really is a new king of the hill when it comes to the largest marijuana stock in North America, and its name is Canopy Growth Corp. (NASDAQOTH:TWMJF). Canopy Growth has the highest individual market share in Canada's medical cannabis market, which is absolutely booming at the moment. According to Health Canada in May, the number of eligible patients has been growing by about 10% a month.
But the real allure with Canopy Growth Corp. -- and all Canadian pot growers as you'll see below -- is the potential that Canada may become the first developed country in the world to legalize recreational weed by July 1, 2018. Legislation introduced by Prime Minister Justin Trudeau hasn't hit any critical roadblocks yet that would derail the bill, leading some pundits to believe the recreational market could add billions in additional revenue.
As icing on the cake, Canopy Growth Corp. also is one of just a handful of growers that's been given the OK to export dried cannabis to countries like Germany, which have legalized medical cannabis. While its profitability has been derailed by costs tied to acquisitions and capacity-expansion investments, it appears to have the makings of a rapidly growing and soon-to-be profitable company.
Cannabis leaves next to biotech lab equipment and test tubes.
IMAGE SOURCE: GETTY IMAGES.
GW Pharmaceuticals: $2.84 billion
Losing the top spot in terms of market cap among pure-play marijuana stocks is GW Pharmaceuticals (NASDAQ:GWPH), the only non-grower on this list. U.K.-based GW Pharmaceuticals is focused on discovering cannabinoids from the cannabis plant and utilizing them to effect positive biologic change.
The biggest positive working in the company's favor has been its pivotal-stage trial results involving Epidiolex, an oral cannabidiol-based drug. Cannabidiol is the non-psychoactive component of cannabis. In two separate phase three studies, each for two rare forms of childhood-onset epilepsy, Dravet syndrome and Lennox-Gastaut syndrome, Epidiolex demonstrated a statistically significant reduction in seizure frequency. If approved by the Food and Drug Administration (FDA), it would become the first cannabinoid-based drug to hit the market and potentially top $500 million in peak annual sales.
Of course, with competition for Dravet syndrome and Lennox-Gastaut syndrome picking up, GW Pharmaceuticals isn't assured a cakewalk.
An indoor commercial cannabis grow farm.
IMAGE SOURCE: GETTY IMAGES.
Aurora Cannabis: $1.47 billion
There's a pretty sizable drop-off to the third-largest marijuana stock, Aurora Cannabis (NASDAQOTH:ACBFF), which is about half the size of GW Pharmaceuticals. Nonetheless, this Canadian medical cannabis grower has grown like a weed over the trailing year, with a 103% gain.
Of the major Canadian medical cannabis players, Aurora Cannabis is the only one that hasn't put together a string of profitable quarters. But it's getting somewhat of a free pass on account of its megaproject known as Aurora Sky. When complete, this 800,000 square-foot facility should be capable of producing 100,000 kilograms of dried cannabis annually. It should also be heavily automated, which is expected to translate into some of the lowest growing costs and highest margins in the industry.
To put this into context, Aurora Cannabis, even with a 40,000 square-foot facility acquisition, doesn't even have 100,000 square feet of growing capacity at the moment. But when Aurora Sky is complete, and if Canada moves to legalize recreational weed, it'll be set to possibly capture around 10% of the country's adult-use market share.
Cannabis buds tipped over from a bottle onto a messy pile of cash.
IMAGE SOURCE: GETTY IMAGES.
MedReleaf: $1.24 billion
Canadian medical cannabis producer MedReleaf (NASDAQOTH:MEDFF), which only went public about six months ago, has already become the fourth-largest pure-play marijuana stock. It also has the most reasonable trailing 12-month P/E of all pot stocks, albeit it's still well above the average for the S&P 500.
Like Canopy Growth and Aurora Cannabis, MedReleaf has benefited from growth in the medical market and the expectation that adult-use weed will be legalized. But there's a bit more going on here than just that. MedReleaf also has two advantages over its peers.
First, it offers a segment of higher-priced cannabis strains for a more affluent clientele. Secondly, it holds nearly half of all market share in cannabis oils in Canada. Cannabis oils sport a higher price point and margin than traditional dried cannabis, which has played a key role in pushing MedReleaf's profits higher by more than 400% in 2017 from the prior-year period.
Following its initial public offering and the cash raised from that offering, MedReleaf is focused on expanding growing capacity at its Bradford, Ontario facility.
Marijuana stocks are overhyped: 10 better buys for you now
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and marijuana stocks were noticeably absent! That's right -- they think these 10 stocks are better buys.
Learn more
*Stock Advisor returns as of November 1, 2017
Sean Williams has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
This Stock Could Be Like Buying Amazon in 1997
Imagine if you had bought Amazon in 1997… a $5,000 investment then would be worth almost $1 million today.
You can't go back and buy Amazon 20 years ago… but we've uncovered what our analysts think is the next-best thing: A special stock with mind-boggling growth potential.
With hundreds of thousands of business customers already signed up, this stock has been described as "strikingly similar to an early Amazon.com."
To learn more about it, click here.
AUTHOR
Sean Williams Sean Williams (TMFUltraLong) A Fool since 2010, and a graduate from UC San Diego with a B.A. in Economics, Sean specializes in the healthcare sector and investment planning. You'll often find him writing about Obamacare, marijuana, drug and device development, Social Security, taxes, retirement issues and general macroeconomic topics of interest.
ARTICLE INFO
Nov 17, 2017 at 8:21AM
Health Care
STOCKS
GW Pharmaceuticals Stock Quote
GW Pharmaceuticals
NASDAQ:GWPH
$115.88 down $-1.67 (-1.42%)
Canopy Growth Corporation Stock Quote
Canopy Growth Corporation
NASDAQOTH:TWMJF
$14.45 up $0.93 (6.88%)
Aurora Cannabis Inc. Stock Quote
Aurora Cannabis Inc.
NASDAQOTH:ACBFF
$4.33 up $0.09 (2.12%)
MEDRELEAF CORP COM NPV Stock Quote
MEDRELEAF CORP COM NPV
NASDAQOTH:MEDFF
$12.79 up $0.60 (4.97%)
READ MORE
GW Pharmaceuticals Is No Longer the Largest Pure-Play Marijuana Stock -- This Is
GW Pharmaceuticals Just Delivered Some Good News About Its Marijuana-Based Drug
Could Marijuana Stock GW Pharmaceuticals Soar More Than 50%?
Legalizing Recreational Marijuana in Colorado Reversed a 14-Year Trend of Rising Opioid-Related Deaths
4 Top Marijuana Stocks to Buy in 2018
Terms of Use Privacy Policy Accessibility Policy Copyright, Trademark and Patent Information Terms and Conditions
© 1995 - 2017The Motley Fool. All rights reserved.
Market data provided by ICE Data Services. ICE Limitations. Powered and implemented by FactSet. Legal Statement.
